Novartis/Alcon Merger Clears FTC Hurdle With Minor Divestiture, But Shareholder Battle Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sells its miotic drug Miochol-E to Bausch & Lomb to avoid anticompetitive charges; a Novartis legal expert says a subset of Alcon's board cannot veto the transaction.